2015
DOI: 10.1177/0269881115612236
|View full text |Cite
|
Sign up to set email alerts
|

Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis

Abstract: The effects of propranolol in the treatment of anxiety disorders have not been systematically evaluated previously. The aim was to conduct a systematic review and meta-analysis of randomised controlled trials, addressing the efficacy of oral propranolol versus placebo or other medication as a treatment for alleviating either state or trait anxiety in patients suffering from anxiety disorders. Eight studies met the inclusion criteria. These studies concerned panic disorder with or without agoraphobia (four stud… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
123
0
8

Year Published

2016
2016
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 181 publications
(132 citation statements)
references
References 60 publications
(83 reference statements)
1
123
0
8
Order By: Relevance
“…Increased salience network connectivity has also been documented in a host of anxiety disorders, notably including PTSD (Peterson et al, 2014). Furthermore, propranolol-another pharmacological agent investigated as an adjunct for PTSD therapy (Brunet et al, 2008, but see Wood et al, 2015;Steenen et al, 2016)-decreases connectivity within the salience network (Hermans et al, 2011). Thus, it is worth considering whether action at the salience network might be an important component of the mechanism by which MDMA operates in MDMA-assisted psychotherapy for PTSD (Mithoefer et al, 2011;Mithoefer et al, 2012;Oehen et al, 2013).…”
Section: Discussionmentioning
confidence: 99%
“…Increased salience network connectivity has also been documented in a host of anxiety disorders, notably including PTSD (Peterson et al, 2014). Furthermore, propranolol-another pharmacological agent investigated as an adjunct for PTSD therapy (Brunet et al, 2008, but see Wood et al, 2015;Steenen et al, 2016)-decreases connectivity within the salience network (Hermans et al, 2011). Thus, it is worth considering whether action at the salience network might be an important component of the mechanism by which MDMA operates in MDMA-assisted psychotherapy for PTSD (Mithoefer et al, 2011;Mithoefer et al, 2012;Oehen et al, 2013).…”
Section: Discussionmentioning
confidence: 99%
“…Desr echerches trĂšsr Ă© centeso nt commencĂ© sur l'intĂ©rĂȘtd up ropanolol dans la prĂ©vention du syndrome de stress post-traumatique aprĂšs un Ă©vĂšnement traumatisant [52,53]. La prescriptiond 'anxiolytiques est possible mais pour un temps court en raison du risque de dĂ©pendance.…”
Section: La Prise En Chargeunclassified
“…Many have successfully used pharmacological agents such as the FDA-approved b-adrenergic antagonist, propranolol, in preclinical studies to prevent reconsolidation of fear memories as a means of memory "erasure" (Debiec and Ledoux 2004). However, translating these achievements to the clinic has come with varying levels of success (Soeter and Kindt 2012;Steenen et al 2016). This has motivated investigations of additional mechanisms, including epigenetic modifications.…”
Section: Epigenetics and The Modulation Of Fear Memorymentioning
confidence: 99%